Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
Radhakrishnan Ramchandren, Charles A SchifferDivision of Hematology/Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USAAbstract: The development of imatinib for the treatment of chronic myeloid leukemia (CML) has proven to be an example of medical success...
Guardado en:
Autores principales: | Radhakrishnan Ramchandren, Charles A Schiffer |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://doaj.org/article/22a41d57922f409f808697601d0692bd |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Long-term safety and efficacy of dasatinib in the treatment of chronic-phase chronic myeloid leukemia patients resistant or intolerant to imatinib
por: Shoumariyeh K, et al.
Publicado: (2014) -
Imatinib in the treatment of chronic myeloid leukemia: current perspectives on optimal dose
por: Waclaw J, et al.
Publicado: (2015) -
First-line therapy of chronic myeloid leukemia – focus on dasatinib
por: Amrein PC
Publicado: (2012) -
EARLY MOLECULAR RESPONSE WITH IMATINIB THERAPY IN CHRONIC MYELOID LEUKEMIA AND ITS ASSOCIATION WITH BASELINE WHITE BLOOD CELL COUNT AND SPLEEN SIZE
por: Abdul Ali Wajid, et al.
Publicado: (2018) -
Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report
por: Zakaria Maat, et al.
Publicado: (2021)